



Vaccibody AS: Siri Torhaug, MD appointed as new Chief Medical Officer

Oslo, October 11th, 2019 – Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, appoints Dr. Siri Torhaug as Chief Medical Officer.

Siri Torhaug is a medical doctor and certified clinical specialist in oncology. She has broad experience in clinical development and translational research within immune oncology, and has led clinical trials from early phase as well as pivotal phase II and III studies during her ten years at Oslo university hospital and Radiumhospitalet, one of Europe`s premier oncology hospital and research centers.

Having spent more than six years in leading pharmaceutical companies, Siri Torhaug brings invaluable experience to the team. She held local and Nordic medical leadership roles during her four years at Novartis including the role of Nordic medical disease lead for melanoma, lung, pipeline and immuno-oncology covering all aspects of early clinical trials in the Nordic countries. In addition, she was instrumental to medical affairs activities and the overall strategy for Novartis` immune-oncology portfolio in the Nordics. In 2017, Siri Torhaug moved to Astrazeneca where she was part of the Nordic Medical Oncology Leadership team, responsible for medical execution.

Siri Torhaug`s knowledge and extensive experience in scientific and medical affairs covering all relevant tumor areas, R&D and general management of cancer drug development will be of great value to Vaccibody when the company continues to develop and expand its clinical trial portfolio in the coming years.

“I am very pleased to welcome Siri Torhaug as Chief Medical Officer of Vaccibody. Siri is a seasoned leader and has deep experience within the immuno-oncology field across technologies including T cell therapy. Her valuable experience covers multiple aspects of clinical development from both the side of the clinician to several years of medical responsibility in big pharma. The Management team and I look forward to working with Siri and to continue Vaccibody`s successful journey”, said Michael Engsig, CEO of Vaccibody. Siri Torhaug continues, “Vaccibody has such a strong momentum and is leading within the field of neoantigen cancer vaccines. I am very excited to join Vaccibody and become a part of this great organization.”

Siri Torhaug will initiate her employment on January 1st, 2020.

About Vaccibody

Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate best-in-class therapeutics to treat cancers with a high unmet medical need. A phase I/IIa neoantigen clinical trial is now enrolling patients with locally advanced or metastatic melanoma, non-small cell lung carcinoma, clear renal cell carcinoma as well as urothelial or squamous cell carcinoma of head and neck. Vaccibody has a collaboration with Nektar Therapeutics, planning to start testing VB10.NEO in combination with bempedaldesleukin (NKTR-214) in squamous cell carcinoma of head and neck in H2 2019. Vaccibody's front runner program (VB10.16) is a therapeutic DNA vaccine against HPV16 induced pre-malignancies and malignancies. The first-in-human study (phase I/IIa), evaluating the safety and immunogenicity of VB10.16 in women with high grade cervical intraepithelial neoplasia (HSIL; CIN 2/3) has published positive 12 months data. Vaccibody has recently started a collaboration with Roche, exploring VB10.16 in combination with their checkpoint inhibitor atezolizumab (Tecentriq™) in up to 50 patients with advanced or recurrent cervical cancer. First patient is expected to be vaccinated in H1 2020. Further information about the company and its drug development programs and capabilities may be found online at <http://www.vaccibody.com>

Contact:

CEO Michael Engsig
Vaccibody AS
Cell: +45 6173 1509
mengsig@vaccibody.com

Vaccibody AS

Oslo Research Park
Gaustadalléen 21
0349 Oslo, Norway